Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

Mediators of Inflammation
Volume 2016 (2016), Article ID 1405924, 10 pages
http://dx.doi.org/10.1155/2016/1405924
Research Article

Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice

1Department of Nephrology, ZhuJiang Hospital, Southern Medical University, Guangzhou 510280, China
2Department of Gerontology, ZhuJiang Hospital, Southern Medical University, Guangzhou 510280, China
3Department of Emergency, ZhuJiang Hospital, Southern Medical University, Guangzhou 510280, China

Received 23 October 2015; Accepted 20 December 2015

Academic Editor: Hannes Neuwirt

Copyright © 2016 Xiao-Wen Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Ritz and S. R. Orth, “Nephropathy in patients with type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 341, no. 15, pp. 1127–1133, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Ritz, I. Rychlik, F. Locatelli, and S. Halimi, “End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions,” American Journal of Kidney Diseases, vol. 34, no. 5, pp. 795–808, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. A. R. Andersen, J. S. Christiansen, J. K. Andersen, S. Kreiner, and T. Deckert, “Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study,” Diabetologia, vol. 25, no. 6, pp. 496–501, 1983. View at Publisher · View at Google Scholar · View at Scopus
  4. G. L. Bakris, M. Williams, L. Dworkin et al., “Preserving renal function in adults with hypertension and diabetes: a consensus approach,” American Journal of Kidney Diseases, vol. 36, no. 3, pp. 646–661, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. T. W. Meyer, P. H. Bennett, and R. G. Nelson, “Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria,” Diabetologia, vol. 42, no. 11, pp. 1341–1344, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Anil Kumar, G. I. Welsh, M. A. Saleem, and R. K. Menon, “Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus,” Frontiers in Endocrinology, vol. 5, article 151, 2014. View at Publisher · View at Google Scholar
  7. F. Chow, E. Ozols, D. J. Nikolic-Paterson, R. C. Atkins, and G. H. Tesch, “Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury,” Kidney International, vol. 65, no. 1, pp. 116–128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. W. H. Yiu, M. Lin, and S. C. W. Tang, “Toll-like receptor activation: from renal inflammation to fibrosis,” Kidney International Supplements, vol. 4, no. 1, pp. 20–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Kanamori, T. Matsubara, A. Mima et al., “Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy,” Biochemical and Biophysical Research Communications, vol. 360, no. 4, pp. 772–777, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Amann, R. Tinzmann, and B. Angelkort, “ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1,” Diabetes Care, vol. 26, no. 8, pp. 2421–2425, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Ren, G. Guan, G. Liu, and G. Liu, “Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats,” Pharmacology, vol. 83, no. 2, pp. 80–87, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Wang, C. Min, X. Rong, T. Fu, X. Huang, and C. Wang, “Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy,” Discovery Medicine, vol. 20, no. 108, pp. 67–77, 2015. View at Google Scholar
  13. S.-I. Masuda, K. Tamura, H. Wakui et al., “Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy,” Hypertension Research, vol. 32, no. 11, pp. 950–955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Nakamura, N. Sasai, I. Hisatome, and K. Ichida, “Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes,” Clinical Pharmacology: Advances and Applications, vol. 6, no. 1, pp. 79–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Hartner, N. Cordasic, B. Klanke et al., “Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress,” Biochimica et Biophysica Acta, vol. 1842, no. 4, pp. 558–565, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Chen, G. Jin, K.-M. Huang et al., “Lycorine suppresses rankl-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo,” Scientific Reports, vol. 5, Article ID 12853, 2015. View at Publisher · View at Google Scholar
  17. U. M. Malyankar, M. Scatena, K. L. Suchland, T. J. Yun, E. A. Clark, and C. M. Giachelli, “Osteoprotegerin is an α(v)β3-induced, NF-κB-dependent survival factor for endothelial cells,” The Journal of Biological Chemistry, vol. 275, no. 28, pp. 20959–20962, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Liu, W. Shi, H. Xiao et al., “Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury,” PLoS ONE, vol. 7, no. 7, Article ID e41331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Leiherer, A. Muendlein, P. Rein et al., “Genome-wide association study reveals a polymorphism in the podocyte receptor RANK for the decline of renal function in coronary patients,” PLoS ONE, vol. 9, no. 12, Article ID e114240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Kiechl, J. Wittmann, A. Giaccari et al., “Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus,” Nature Medicine, vol. 19, no. 3, pp. 358–363, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Zhong, A. C. K. Chung, H. Y. Chen et al., “MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes,” Diabetologia, vol. 56, no. 3, pp. 663–674, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Bai, X. Li, J. Tian, and Z. Zhou, “Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local akt in early experimental diabetes,” PLoS ONE, vol. 9, no. 4, Article ID e96117, 2014. View at Publisher · View at Google Scholar
  23. E. Gagliardini, S. Conti, A. Benigni, G. Remuzzi, and A. Remuzzi, “Imaging of the porous ultrastructure of the glomerular epithelial filtration slit,” Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2081–2089, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Zhao, S.-J. Chen, J.-C. Wang et al., “Sesquiterpene lactones inhibit advanced oxidation protein product-induced MCP-1 expression in podocytes via an IKK/NF-κB-dependent mechanism,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 934058, 13 pages, 2015. View at Publisher · View at Google Scholar
  25. Z.-H. Yang and X.-D. Peng, “Insulin resistance and heart injury in rats with insulin resistance or type 2 diabetes mellitus,” Acta Cardiologica, vol. 65, no. 3, pp. 329–335, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright, and T. Unger, “International union of pharmacology. XXIII. The angiotensin II receptors,” Pharmacological Reviews, vol. 52, no. 3, pp. 415–472, 2000. View at Google Scholar · View at Scopus
  27. H.-H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, and P. Arner, “The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 345, no. 12, pp. 870–878, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. E. J. Lewis, L. G. Hunsicker, W. R. Clarke et al., “Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes,” The New England Journal of Medicine, vol. 345, no. 12, pp. 851–860, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Tunçdemir and M. Öztürk, “The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy,” Acta Histochemica, vol. 113, no. 8, pp. 826–832, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Bonnet, M. E. Cooper, H. Kawachi, T. J. Allen, G. Boner, and Z. Cao, “Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension,” Diabetologia, vol. 44, no. 7, pp. 874–877, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Schrader, W. Rennekamp, U. Niebergall et al., “Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death,” Diabetologia, vol. 50, no. 6, pp. 1243–1247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Lorz, A. Benito-Martin, A. Boucherot et al., “The death ligand TRAIL in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 5, pp. 904–914, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Candido, “The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney,” Current Opinion in Nephrology and Hypertension, vol. 23, no. 1, pp. 69–74, 2014. View at Publisher · View at Google Scholar · View at Scopus